Novel HDL-based therapeutic agents

Pharmacology and Therapeutics

Volumn 135, Issue 1, 2012, Pages 18-30

  Joy, Tisha R ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Apo A I Milano; Apo A I mimetic; CETP inhibitors; D 4F; reconstituted HDL; RVX 208

Indexed keywords

ALDOSTERONE; ANACETRAPIB; APL 180; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CREATINE KINASE; CSL 111; D 4F; DALCETRAPIB; ETC 216; EVACETRAPIB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; L 4F; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICLOSAMIDE; PRAVASTATIN; ROSUVASTATIN; RVX 208; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALDOSTERONE BLOOD LEVEL; ALLERGY; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CLAUDICATION; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; ECG ABNORMALITY; ELECTROLYTE BLOOD LEVEL; EPIDEMIOLOGICAL DATA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPOALPHALIPOPROTEINEMIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION SIZE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INFLAMMATION; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; LYMPH NODE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; MYALGIA; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY TRACT DISEASE; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; MOLECULAR MIMICRY; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84861343798     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.03.004     Document Type: Review

References (91)

1. G.M. Anantharamaiah, J.L. Jones, C.G. Brouillette, C.F. Schmidt, B.H. Chung, and T.A. Hughes Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine J Biol Chem 260 18 1985 10248 10255 (Pubitemid 16246560)
2. D. Bailey, R. Jahagirdar, A. Gordon, A. Hafiane, S. Campbell, and S. Chatur RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J Am Coll Cardiol 55 23 2010 2580 2589
3. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, and M. Komajda Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 21 2007 2109 2122 (Pubitemid 350146106)
4. R.J. Bisoendial, G.K. Hovingh, K. El Harchaoui, J.H. Levels, S. Tsimikas, and K. Pu Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia Arterioscler Thromb Vasc Biol 25 9 2005 e133 e134
5. R.J. Bisoendial, G.K. Hovingh, J.H. Levels, P.G. Lerch, I. Andresen, and M.R. Hayden Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein Circulation 107 23 2003 2944 2948 (Pubitemid 36736637)
6. L.T. Bloedon, R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, and B.J. DeGroot Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients J Lipid Res 49 6 2008 1344 1352
7. D. Bloomfield, G.L. Carlson, A. Sapre, D. Tribble, J.M. McKenney, and T.W. Littlejohn III Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am Heart J 157 2 2009 352 360 e352.
8. W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, and K. Koprowicz Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 24 2011 2255 2267
9. M.L. Bots, F.L. Visseren, G.W. Evans, W.A. Riley, J.H. Revkin, and C.H. Tegeler Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 9582 2007 153 160 (Pubitemid 47042895)
10. G.M. Buga, M. Navab, S. Imaizumi, S.T. Reddy, B. Yekta, and G. Hough L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation Arterioscler Thromb Vasc Biol 30 2 2010 283 289
11. A.C. Calkin, B.G. Drew, A. Ono, S.J. Duffy, M.V. Gordon, and S.M. Schoenwaelder Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux Circulation 120 21 2009 2095 2104
12. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, and A.M. Gotto Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 25 2010 2406 2415
13. G. Cao, T.P. Beyer, Y. Zhang, R.J. Schmidt, Y.Q. Chen, and S.L. Cockerham Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure J Lipid Res 52 12 2011 2169 2176
14. E. Carballo-Jane, Z. Chen, E. O'Neill, J. Wang, C. Burton, and C.H. Chang ApoA-I mimetic peptides promote pre-beta HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose Bioorg Med Chem 18 24 2010 8669 8678
15. X. Chen, C. Burton, X. Song, L. McNamara, A. Langella, and S. Cianetti An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration Int J Biol Sci 5 5 2009 489 499
16. R. Chenevard, D. Hurlimann, L. Spieker, M. Bechir, F. Enseleit, and M. Hermann Reconstituted HDL in acute coronary syndromes Cardiovasc Ther 30 2 2012 e51 e57
17. G. Cimmino, B. Ibanez, G. Vilahur, W.S. Speidl, V. Fuster, and L. Badimon Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano) J Cell Mol Med 13 9B 2009 3226 3235
18. M.H. Davidson, J.M. McKenney, C.L. Shear, and J.H. Revkin Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels J Am Coll Cardiol 48 9 2006 1774 1781 (Pubitemid 44648633)
19. G.J. de Grooth, J.A. Kuivenhoven, A.F. Stalenhoef, J. de Graaf, A.H. Zwinderman, and J.L. Posma Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study Circulation 105 18 2002 2159 2165 (Pubitemid 34517159)
20. H.M. Den Ruijter, R. Franssen, A.O. Verkerk, D.F. van Wijk, S.F. Vaessen, and A.G. Holleboom Reconstituted high-density lipoprotein shortens cardiac repolarization J Am Coll Cardiol 58 1 2011 40 44
21. M. Derks, M. Abt, A. Mwangi, and G. Meneses-Lorente Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing Eur J Clin Pharmacol 66 8 2010 775 783
22. M. Derks, M. Abt, G. Parr, G. Meneses-Lorente, A.M. Young, and M. Phelan No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin Expert Opin Investig Drugs 19 10 2010 1135 1145
23. M. Derks, M. Abt, and M. Phelan Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe Br J Clin Pharmacol 70 6 2010 825 833
24. M. Derks, M. Abt, M. Phelan, L. Turnbull, G. Meneses-Lorente, and N. Bech Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions J Clin Pharmacol 50 10 2010 1188 1201
25. M. Derks, S. Fowler, and O. Kuhlmann In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates Curr Med Res Opin 25 4 2009 891 902
26. M. Derks, S. Fowler, and O. Kuhlmann A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib Clin Ther 31 3 2009 586 599
27. M. Derks, H. Kawamura, M. Abt, G. Meneses-Lorente, M. Phelan, and T. Ishikawa Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers Clin Ther 33 6 2011 754 765
28. B.G. Drew, S.J. Duffy, M.F. Formosa, A.K. Natoli, D.C. Henstridge, and S.A. Penfold High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus Circulation 119 15 2009 2103 2111
29. E. Favari, M. Gomaraschi, I. Zanotti, F. Bernini, M. Lee-Rueckert, and P.T. Kovanen A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux J Biol Chem 282 8 2007 5125 5132 (Pubitemid 47093758)
30. Z.A. Fayad, V. Mani, M. Woodward, D. Kallend, M. Abt, and T. Burgess Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial Lancet 378 9802 2011 1547 1559
31. C.J. Fielding, V.G. Shore, and P.E. Fielding A protein cofactor of lecithin:cholesterol acyltransferase Biochem Biophys Res Commun 46 4 1972 1493 1498
32. M.J. Forrest, D. Bloomfield, R.J. Briscoe, P.N. Brown, A.M. Cumiskey, and J. Ehrhart Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br J Pharmacol 154 7 2008 1465 1473
33. D.W. Garber, G. Datta, M. Chaddha, M.N. Palgunachari, S.Y. Hama, and M. Navab A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis J Lipid Res 42 4 2001 545 552 (Pubitemid 32366997)
34. A. Goldberg, P. Alagona Jr., D.M. Capuzzi, J. Guyton, J.M. Morgan, and J. Rodgers Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia Am J Cardiol 85 9 2000 1100 1105 (Pubitemid 30214256)
35. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 5 1977 707 714 (Pubitemid 8110784)
36. F. Hermann, F. Enseleit, L.E. Spieker, D. Periat, I. Sudano, and M. Hermann Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia Thromb Res 123 3 2009 460 465
37. R. Hovorka, M.N. Nanjee, C.J. Cooke, I.P. Miller, W.L. Olszewski, and N.E. Miller Mass kinetics of apolipoprotein A-I in interstitial fluid after administration of intravenous apolipoprotein A-I/lecithin discs in humans J Lipid Res 47 5 2006 975 981 (Pubitemid 43764693)
38. X. Hu, J.D. Dietz, C. Xia, D.R. Knight, W.T. Loging, and A.H. Smith Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition Endocrinology 150 5 2009 2211 2219
39. N. Hyka, J.M. Dayer, C. Modoux, T. Kohno, C.K. Edwards 3rd, and P. Roux-Lombard Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes Blood 97 8 2001 2381 2389 (Pubitemid 32291485)
40. B. Ibanez, C. Giannarelli, G. Cimmino, C.G. Santos-Gallego, M. Alique, and A. Pinero Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type) Atherosclerosis 220 1 2012 72 77
41. B. Ibanez, G. Vilahur, G. Cimmino, W.S. Speidl, A. Pinero, and B.G. Choi Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis J Am Coll Cardiol 51 11 2008 1104 1109 (Pubitemid 351374767)
42. A. Inazu, M.L. Brown, C.B. Hesler, L.B. Agellon, J. Koizumi, and K. Takata Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation N Engl J Med 323 18 1990 1234 1238 (Pubitemid 20366528)
43. J.J. Kastelein, S.I. van Leuven, L. Burgess, G.W. Evans, J.A. Kuivenhoven, and P.J. Barter Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 16 2007 1620 1630 (Pubitemid 46631671)
44. J. Koizumi, H. Mabuchi, A. Yoshimura, I. Michishita, M. Takeda, and H. Itoh Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia Atherosclerosis 58 1-3 1985 175 186 (Pubitemid 16173307)
45. A. Kontush, and M.J. Chapman Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis Pharmacol Rev 58 3 2006 342 374 (Pubitemid 44394906)
46. R. Krishna, M.S. Anderson, A.J. Bergman, B. Jin, M. Fallon, and J. Cote Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Lancet 370 9603 2007 1907 1914 (Pubitemid 350192656)
47. R. Krishna, A.J. Bergman, B. Jin, M. Fallon, J. Cote, and P. Van Hoydonck Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Clin Pharmacol Ther 84 6 2008 679 683
48. R. Krishna, A.J. Bergman, B. Jin, A. Garg, B. Roadcap, and R. Chiou Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers J Clin Pharmacol 49 1 2009 80 87
49. R. Krishna, A. Garg, B. Jin, S.S. Keshavarz, F.A. Bieberdorf, and J. Chodakewitz Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Br J Clin Pharmacol 67 5 2009 520 526
50. R. Krishna, A. Garg, D. Panebianco, J. Cote, A.J. Bergman, and P. Van Hoydonck Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Br J Clin Pharmacol 68 4 2009 535 545
51. J.A. Kuivenhoven, G.J. de Grooth, H. Kawamura, A.H. Klerkx, F. Wilhelm, and M.D. Trip Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia Am J Cardiol 95 9 2005 1085 1088 (Pubitemid 40544314)
52. C. Lebherz, J. Sanmiguel, J.M. Wilson, and D.J. Rader Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent Cardiovasc Diabetol 6 2007 15
53. X. Li, K.Y. Chyu, J.R. Faria Neto, J. Yano, N. Nathwani, and C. Ferreira Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice Circulation 110 12 2004 1701 1705 (Pubitemid 39297996)
54. M. Marchesi, E.A. Booth, T. Davis, C.L. Bisgaier, and B.R. Lucchesi Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury J Pharmacol Exp Ther 311 3 2004 1023 1031 (Pubitemid 39612707)
55. J.M. McKenney, M.H. Davidson, C.L. Shear, and J.H. Revkin Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin J Am Coll Cardiol 48 9 2006 1782 1790 (Pubitemid 44648632)
56. A.J. Mendez, G.M. Anantharamaiah, J.P. Segrest, and J.F. Oram Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol J Clin Invest 94 4 1994 1698 1705 (Pubitemid 24309896)
57. C. Morgantini, S. Imaizumi, V. Grijalva, M. Navab, A.M. Fogelman, and S.T. Reddy Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes Diabetes 59 12 2010 3223 3228
58. M. Navab, G.M. Anantharamaiah, S. Hama, D.W. Garber, M. Chaddha, and G. Hough Oral administration of an Apo A-I mimetic peptide synthesized from d-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol Circulation 105 3 2002 290 292 (Pubitemid 34106174)
59. M. Navab, G.M. Anantharamaiah, S. Hama, G. Hough, S.T. Reddy, and J.S. Frank D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice Arterioscler Thromb Vasc Biol 25 7 2005 1426 1432 (Pubitemid 40923363)
60. M. Navab, G.M. Anantharamaiah, S.T. Reddy, S. Hama, G. Hough, and V.R. Grijalva Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice Circulation 109 25 2004 3215 3220
61. M. Navab, G.M. Anantharamaiah, S.T. Reddy, B.J. Van Lenten, G. Datta, and D. Garber Potential clinical utility of high-density lipoprotein-mimetic peptides Curr Opin Lipidol 17 4 2006 440 444 (Pubitemid 44079483)
62. M. Navab, P. Ruchala, A.J. Waring, R.I. Lehrer, S. Hama, and G. Hough A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all l-amino acids J Lipid Res 50 8 2009 1538 1547
63. S.J. Nicholls, H.B. Brewer, J.J. Kastelein, K.A. Krueger, M.D. Wang, and M. Shao Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 19 2011 2099 2109
64. S.J. Nicholls, B. Cutri, S.G. Worthley, P. Kee, K.A. Rye, and S. Bao Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits Arterioscler Thromb Vasc Biol 25 11 2005 2416 2421 (Pubitemid 41552664)
65. S.J. Nicholls, A. Gordon, J. Johansson, K. Wolski, C.M. Ballantyne, and J.J. Kastelein Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial J Am Coll Cardiol 57 9 2011 1111 1119
66. S.J. Nicholls, E.M. Tuzcu, I. Sipahi, P. Schoenhagen, T. Crowe, and S. Kapadia Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano J Am Coll Cardiol 47 5 2006 992 997
67. E.J. Niesor, C. Magg, N. Ogawa, H. Okamoto, E. von der Mark, and H. Matile Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport J Lipid Res 51 12 2010 3443 3454
68. M. Nieuwdorp, M. Vergeer, R.J. Bisoendial, J. op 't Roodt, H. Levels, and R.S. Birjmohun Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus Diabetologia 51 6 2008 1081 1084
69. S.E. Nissen, J.C. Tardif, S.J. Nicholls, J.H. Revkin, C.L. Shear, and W.T. Duggan Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 13 2007 1304 1316 (Pubitemid 46513296)
70. S.E. Nissen, T. Tsunoda, E.M. Tuzcu, P. Schoenhagen, C.J. Cooper, and M. Yasin Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 17 2003 2292 2300 (Pubitemid 37430562)
71. E. O'Neill, C.P. Sparrow, Y. Chen, S. Eveland, B. Frantz-Wattley, and D. Milot Identification and characterization of MK-0859, a novel cholesteryl ester transfer protein inhibitor J Clin Lipidol 1 5 2007 367
72. J. Ou, Z. Ou, D.W. Jones, S. Holzhauer, O.A. Hatoum, and A.W. Ackerman L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease Circulation 107 18 2003 2337 2341 (Pubitemid 36578505)
73. J. Ou, J. Wang, H. Xu, Z. Ou, M.G. Sorci-Thomas, and D.W. Jones Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet Circ Res 97 11 2005 1190 1197
74. C. Parolini, M. Marchesi, P. Lorenzon, M. Castano, E. Balconi, and L. Miragoli Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging J Am Coll Cardiol 51 11 2008 1098 1103 (Pubitemid 351374769)
75. S. Patel, B.G. Drew, S. Nakhla, S.J. Duffy, A.J. Murphy, and P.J. Barter Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes J Am Coll Cardiol 53 11 2009 962 971
76. M. Ranalletta, K.K. Bierilo, Y. Chen, D. Milot, Q. Chen, and E. Tung Biochemical characterization of cholesteryl ester transfer protein inhibitors J Lipid Res 51 9 2010 2739 2752
77. A.A. Sethi, J.A. Stonik, F. Thomas, S.J. Demosky, M. Amar, and E. Neufeld Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides J Biol Chem 283 47 2008 32273 32282
78. J.A. Shaw, A. Bobik, A. Murphy, P. Kanellakis, P. Blombery, and N. Mukhamedova Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque Circ Res 103 10 2008 1084 1091
79. C.R. Sirtori, L. Calabresi, G. Franceschini, D. Baldassarre, M. Amato, and J. Johansson Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study Circulation 103 15 2001 1949 1954 (Pubitemid 32322221)
80. X. Song, P. Fischer, X. Chen, C. Burton, and J. Wang An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI Int J Biol Sci 5 7 2009 637 646
81. L.E. Spieker, I. Sudano, D. Hurlimann, P.G. Lerch, M.G. Lang, and C. Binggeli High-density lipoprotein restores endothelial function in hypercholesterolemic men Circulation 105 12 2002 1399 1402 (Pubitemid 34263266)
82. E.A. Stein, E.M. Roth, J.M. Rhyne, T. Burgess, D. Kallend, and J.G. Robinson Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial Eur Heart J 31 4 2010 480 488
83. E.A. Stein, E.S. Stroes, G. Steiner, B.M. Buckley, A.M. Capponi, and T. Burgess Safety and tolerability of dalcetrapib Am J Cardiol 104 1 2009 82 91
84. E.S. Stroes, J.J. Kastelein, A. Benardeau, O. Kuhlmann, D. Blum, and L.A. Campos Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats Br J Pharmacol 158 7 2009 1763 1770
85. F. Tabet, A.T. Remaley, A.I. Segaliny, J. Millet, L. Yan, and S. Nakhla The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro Arterioscler Thromb Vasc Biol 30 2 2010 246 252
86. A.R. Tall Plasma cholesteryl ester transfer protein J Lipid Res 34 8 1993 1255 1274 (Pubitemid 23230305)
87. J.C. Tardif, J. Gregoire, P.L. L'Allier, R. Ibrahim, J. Lesperance, and T.M. Heinonen Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 15 2007 1675 1682 (Pubitemid 46631626)
88. C.E. Watson, N. Weissbach, L. Kjems, S. Ayalasomayajula, Y. Zhang, and I. Chang Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function J Lipid Res 52 2 2011 361 373
89. G.L. Weibel, E.T. Alexander, M.R. Joshi, D.J. Rader, S. Lund-Katz, and M.C. Phillips Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux Arterioscler Thromb Vasc Biol 27 9 2007 2022 2029 (Pubitemid 47312313)
90. G.D. Wool, T. Vaisar, C.A. Reardon, and G.S. Getz An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide J Lipid Res 50 9 2009 1889 1900
91. Y. Yui, T. Aoyama, H. Morishita, M. Takahashi, Y. Takatsu, and C. Kawai Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I J Clin Invest 82 3 1988 803 807